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Abstract
Background: The endothelial nitric oxide synthase gene (NOS3) has been proposed as a candidate gene for
preeclampsia. However, studies so far have produced conflicting results. This study examines the specific role of
variants and haplotypes of the NOS3 gene in a population of Caucasian origin.
Methods: We examined the association of three common variants of the NOS3 gene (4b/a, T-786C and G894T)
and their haplotypes in a case-control sample of 102 patients with preeclampsia and 176 women with a history of
uncomplicated pregnancies. Genotyping for the NOS3 variants was performed and odds ratios and 95% confidence
intervals were obtained to evaluate the association between NOS3 polymorphisms and preeclampsia.
Results: The single locus analysis for the three variants using various genetic models and a model-free approach
revealed no significant association in relation to clinical status. The analysis of haplotypes also showed lack of
significant association.
Conclusions: Given the limitations of the candidate-gene approach in investigating complex traits, the evidence of
our study does not support the major contributory role of these common NOS3 variants in preeclampsia. Future
larger studies may help in elucidating the genetics of preeclampsia further.
Background
Preeclampsia is a medical condition in which high blood
pressure and elevated urinary excretion of protein
develop in pregnancy [1]. Family-based studies have
shown that genetic factors may play a role in pree-
clampsia [2]. In addition, candidate-gene association stu-
dies (GAS) on preeclampsia have not produced
conclusive results so far [3]. However, the pathogenesis
of preeclampsia is poorly understood and the search for
low-penetrance genes by hypothesis-driven candidate-
gene studies (genetic association study-GAS) and
hypothesis-free genome-wide association studies is
ongoing [4].
The leading hypotheses, concerning the pathogenesis
of preeclampsia, are based on disturbed placental func-
tion and impaired remodelling of the spiral arteries [5].
Endothelial nitric oxide synthase (NOS3) is an
important regulator of vascular tone and contributes to
the reduction of the uteroplacental resistance seen in
normal pregnancy [6-8]. Therefore, the endothelial nitric
oxide synthase gene (NOS3), located at the 7q35-q36
region, has emerged as a logical candidate gene in the
development of preeclampsia. Variants (polymorphisms)
of the NOS3 gene have been investigated for association
with preeclampsia and other disorders such as hyperten-
sion [9,10]. The three most common variants examined
for clinical relevance, based on their potential functional
effects are [11]: (i) a G894T substitution in exon 7
resulting in a Glu to Asp substitution at codon 298
(rs1799983), (ii) an insertion-deletion in intron 4 (4a/b)
consisting of two alleles (the a*-deletion which has four
tandem 27-bp repeats and the b*-insertion having five
repeats), and (iii) a T786C substitution in the promoter
region (rs2070744). A whole genome-scan meta-analysis
for preeclampsia has already identified the locus of
NOS3 gene as a promising candidate for preeclampsia
susceptibility [2], although linkage studies seem to
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rather than preeclampsia [12,13].
Previous GAS that investigated the association
between NOS3 variants and preeclampsia have produced
controversial or inconclusive results and the replication
record of these studies is relatively poor [14,15]. There-
fore, the status of association for the NOS3 variants
remains ambiguous. In this project we aimed to repli-
cate previous findings on the association between the
three most commonly investigated NOS3 polymorph-
isms (4b/a, T-786C and G894T) and preeclampsia, in a
GAS conducted on a homogeneous population of Cau-
casian origin (Greeks). These variants were chosen
because of their potential functional implications and
their high minor allele frequency [16-18]. An analysis of
haplotypes was also performed [19].
Methods
Study population
A total of 102 cases with preeclampsia and 176 female
controls were recruited from the Department of Obste-
trics and Gynecology, University Hospital of Larissa.
Preeclampsia was defined as new hypertension (systolic
blood pressure ≥140 mmHg or diastolic blood pressure
≥90 mmHg) and substantial proteinuria (>300 mg in 24
h) at or after 20 weeks’ gestation [20]. The study proto-
col was approved by the Institute Ethics Committee and
all subjects provided a written informed consent. All
controls faced pregnancies without complications and
they were free of preeclampsia history. The controls
w e r eu n r e l a t e db yb l o o dt oc a s e s ,a n da l la p a r tf r o m3
(1.7%) were delivered at term. All study participants
were of Caucasian origin whereas women with previous
renal disease, diabetes, or history of metabolic disorders
were excluded from the patient sample. A blood sample
for biochemical measurements and DNA extraction was
taken from each individual.
Laboratory assays
Genomic DNA was extracted from whole blood using
the QIAamp DNA blood kit (QIAGEN, Valencia, CA,
USA) following the manufacturer’s instruction. Genotyp-
ing of each polymorphism was performed by amplifica-
tion from 50 to 100 ng of genomic DNA. The primer
sequences used and the laboratory conditions for geno-
typing (polymerase chain reaction, restriction enzymes,
agarose electrophoresis) for each NOS3 polymorphism
have been previously described [16-18]. Genotyping was
performed by laboratory personnel blinded to clinical
status.
Data Analysis
Continues variables were compared using the Mann-
Whitney non-parametric test. Categorical variables were
compared using the Chi-square test. The genotypic dis-
tribution in the control group was tested for departing
from the Hardy-Weinberg Equilibrium (HWE) and the
existence of linkage disequilibrium (LD) between the
two polymorphisms in both cases and control was tested
by using exact tests according to Weir [21]. The haplo-
type frequencies were estimated and compared using
SHEsis [22]. The association between genotype distribu-
tion and clinical status was tested using the chi-square
test. The dominant and recessive models of the cases
was compared to the control group using a logistic
model. The significance of the genetic models was also
tested using the Fisher’se x a c tt e s t .T h ec o m p a r i s o n s
associations were expressed in terms of odds ratio (OR),
unadjusted and adjusted for age, with the corresponding
95% confidence interval (CI). The statistical analysis was
performed using SPSS v11.5 (SPSS Inc.). A result was
considered statistically significant when P < 0.05.
Results
A total of 102 cases and 176 controls were analyzed.
The mean age (±SD) was 30.64 ± 6.32 and 29.60 ± 5.18
for cases and controls respectively; all subjects were
females. The clinical characteristics of the enrolled sub-
j e c t sa r es h o w ni nT a b l e1 .T h ed i s t r i b u t i o n so ft h e
NOS3 4b/a, T-786C and G894T genotypes were not
associated with clinical status and are presented in
Table 2. The generalized ORs for 4b/a, T-786C and
G894T polymorphisms were ORG = 0.79 (0.48-1.29),
ORG = 0.93 (0.61-1.43) and ORG = 0.86 (0.56-1.32),
respectively. The genotype distribution in controls was
in HWE for all polymorphisms, indicating lack of strati-
fication and/or genotyping error (p = 0.99 for 4b/a, p =
0.99 for T-786C and p = 0.090 for G894T).
Table 3 shows the association results for the allele
contrast, the recessive and dominant models for the
mutant alleles. None of the polymorphism showed sig-
nificant association with development of preeclampsia
for allele contrast, the recessive and dominant models.
Table 1 Characteristics of the study subjects
Cases Controls P-value
N 102 176
Age (years) 30.64 ± 6.32 29.60 ± 5.18 0.14
Delivery weeks 35.41 ± 3.43 38.58 ± 2.14 <0.01
Birth weight (g) 2266.5 ± 839 3078.0 ± 572 <0.01
First parity 74 (72.5%) 78 (44.3%) <0.01
Systolic BP 161.66 ± 10.3 115.84 ± 10.9 <0.01
Diastolic BP 92.70 ± 8.47 70.40 ± 7.54 <0.01
Smoking before/
during pregnancy
30 (29.4%)/
6 (5.9%)
62 (35.2%)/
16 (9.1%)
0.32/
0.34
Twin pregnancies 8 (7.8%) 3 (1.7%) 0.01
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Page 2 of 5The unadjusted ORs for the allele contrast were OR =
0.78 (0.50-1.21) for 4b/a, OR = 0.94 (0.66-1.34) for T-
786C and OR = 0.91 (0.65-1.30) for G894T. The age-
adjusted ORs produced similar results.
The LD results are shown id Table 4. In both the patient
and control populations, the 4b/a and T-786C polymorph-
isms were in LD (p = 0.02 and p < 0.01, respectively). In
addition, the T-786C and G894T polymorphisms were in
LD (p < 0.01 for both cases and controls). The distribution
of the estimated haplotype distribution of the two NOS3
polymorphisms for cases and controls is presented in
Table 5. The estimated haplotype frequencies were similar
in cases and controls. The global test of association was
not significant for the comparison of haplotypes between
cases and controls (p = 0.71).
Discussion
This study evaluated relations between common genetic
variants and haplotypes in the NOS3 gene with pree-
clampsia. The single locus analysis among the three
most commonly studied polymorphisms (4b/a, T-786C
and G894T) revealed lack of association. The analysis of
haplotypes also showed non-significant association.
The conclusion reached in the GAS was based on
relatively small number of participants for each gene
polymorphism and therefore, any inferences have to be
cautious. Candidate-gene studies have a tendency to
lack the power to detect weak genetic contributions of
common variants [19,23]. For example, in order to
achieve a power >80% to identify a modest genetic effect
(odds ratio 1.2) of a polymorphism present in 10% of
individuals, a sample size of 10,000 subjects or more
would be needed [23]. Therefore, the sample sizes
required to predict association have to be far beyond
what is currently available and no single institution or
entity alone will be able to provide a reasonable number
of patients. Meta-analysis of multiple studies has clearly
a role in offering an analysis with the potential for
enhanced power [19].
It has been reported that the polymorphisms might be
in linkage disequilibrium and interaction of the poly-
morphisms within haplotypes can be a major determi-
nant of disease susceptibility than the individual
polymorphism [11]. Thus, individual NOS3 genotypes
might not be reliable markers of risk for developing pre-
eclampsia. The haplotype analysis approach is expected
to be more powerful than single-marker analysis,
because of the ancestral structure incarcerated in the
Table 2 Distribution (%) of the NOS3 4b/a, T-786C and
G894T genotypes among cases and control subjects
SNP Genotype Cases
(n = 102)
Controls
(n = 176)
p-value
4b/a bb 66.7 61.9 0.316
ORG = 0.79 (0.48-1.29)
ab 32.4 34.1
aa 0.98 3.98
T-786C CC 13.7 15.9 0.868
ORG = 0.93 (0.61-1.43)
TC 50 47.7
TT 36.3 35.2
G894T TT 16.7 13.6 0.237
ORG = 0.86 (0.56-1.32)
GT 37.3 47.7
GG 46.1 38.6
The p-values and the generalized odds ratios (ORG) with their respective 95%
confidence intervals for testing the association between genotype distribution
of each polymorphism and susceptibility to preeclampsia are shown.
Table 3 Association results
SNP Genetic contrast OR (95% CI) p-value ORadjusted (95% CI)
4b/a Allele contrast (b vs. a) 0.78 (0.50-1.21) 0.27
Recessive model 0.81 (0.49-1.36) 0.43 0.81 (0.48-1.35)
Dominant model 0.24 (0.03-1.97) 0.18 0.24 (0.03-1.97)
T-786C Allele contrast (C vs. T) 0.94 (0.66-1.34) 0.73
Recessive model 0.83 (0.41-1.17) 0.59 0.81 (0.40-1.63)
Dominant model 0.97 (0.59-1.62) 0.91 0.93 (0.56-1.56)
G894T Allele contrast (T vs. G) 0.91 (0.65-1.30) 0.60
Recessive model 1.27 (0.65-2.49) 0.49 1.25 (0.63-2.46)
Dominant model 0.74 (0.45-1.21) 0.23 0.72 (0.439-1.19)
Odds Ratio (OR) and the corresponding 95% Confidence Intervals (CIs) for testing the association between preeclampsia and NOS3 4b/a, T-786C and G894T
polymorphisms for the allele contrast, the dominant and recessive models. The ORs adjusted for age are also shown.
Table 4 D’,r
2 and p-values for testing linkage
disequilibrium between pairs of SNPs for cases and
controls (in brackets)
T-786C G894T
4b/a D’ = 0.66 (0.63)
r2 = 0.14 (0.15)
p = 0.02 (<0.01)
D’ = 0.59 (0.54)
r2 = 0.04 (0.05)
p = 0.10 (0.11)
T-786C - D’ = 0.45 (0.38)
r2 = 0.17 (0.13)
p < 0.01 (<0.01)
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Page 3 of 5distribution of haplotypes [10]. Particularly if the mar-
kers used define mutations within functional DNA, then
the haplotypes composed of these markers can have
more of a biological role. In our analysis, we focused on
haplotypes defined by the three most commonly investi-
gated and potentially functional NOS3 variants (instead
of other tested variants or HapMap tagging polymorph-
isms) because we aimed to replicate the already exam-
ined associations [9,24,25].
Interestingly, 13 studies [9,24-35] have reported posi-
tive association for the variants NOS3 gene, whereas the
two published meta-analyses and other individual stu-
dies did not replicate the findings [14,15,36,37]. Thus,
the available evidence from candidate-gene approach
cannot support a major contributory role of NOS3 var-
iants in preeclampsia pathogenesis. Since predicting the
functional credentials of most genetic variants remains
problematic, obtaining robust replication of positive
association findings proves difficult [38]. Moreover, the
multifactorial etiology of common disorders involving
complex epistatic and gene-environment interactions
reduces the likelihood that a single type of studies, such
as gene-candidate association studies, could provide
conclusive inferences. An integration approach combin-
ing different kinds of genetic data analysis (i.e. genomic
convergence of GAS, GWAS, genome-scans and micro-
arrays) may be more effective in identifying valid genetic
loci [39,40].
In conclusion, the genetic association study did not
replicate a significant association for the NOS3 variants
and haplotypes. The results of the present individual
GAS should be interpreted with caution since the num-
ber of participants were relatively small. However, pree-
clampsia is a complex disease with multifactorial
etiology and therefore, a minor contributory pathoge-
netic role of NOS3 variants in conjunction with other
genetic or environmental factors cannot be excluded
[41]. Collaborative research in preeclampsia may help in
identifying the contributing role of variants by perform-
ing GAS and genome-wide association studies with
adequate power [42]. Furthermore, the design of rigor-
ous studies for investigating epistatic and gene-environ-
ment interactions and the utilization of data generated
by genomic studies may help in deriving more conclu-
sive claims about the genetics of preeclampsia.
Conclusions
The single locus analysis and the analysis of haplotypes
failed to demonstrate a significant association between
preeclampsia and three common NOS3 polymorphisms.
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